Skip to content
DNDi Logo
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • DNDi NORTH AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT US
        • ABOUT US
        • BUSINESS MODEL
        • DNDi‘s POLICIES
        • DNDi WORLDWIDE
        • OUR PEOPLE
        • ANNUAL REPORTS
        • JOB OPPORTUNITIES
        • REQUESTS FOR PROPOSALS
        • CONTACT US
    • Close
  • DISEASES & PROJECTS
        • DISEASES
        • SLEEPING SICKNESS
        • LEISHMANIASIS
        • CHAGAS DISEASE
        • PAEDIATRIC HIV
        • FILARIAL DISEASE
        • MYCETOMA
        • HEPATITIS C
        • PROJECT PORTFOLIO
        • GLOBAL ANTIBIOTIC R&D PARTNERSHIP (GARDP)
        • TARGET PRODUCT PROFILES
        • CLINICAL TRIALS
        • OPEN INNOVATION PORTAL
    • Close
  • ACHIEVEMENTS
      • DNDi ACHIEVEMENTS
      • FEXINIDAZOLE
        Sleeping sickness
      • SUPERBOOSTER THERAPY
        Paediatric HIV/TB
      • NEW VL TREATMENTS – ASIA
        Visceral leishmaniasis
      • PAEDIATRIC BENZNIDAZOLE
        Chagas
      • SSG&PM
        Visceral leishmaniasis
      • NECT
        Sleeping sickness
      • ASMQ
        Malaria
      • ASAQ
        Malaria
    • Close
  • STRENGTHENING CAPACITY
        • OVERVIEW
        • TECHNOLOGY TRANSFERS
        • CHAGAS PLATFORM
        • HAT PLATFORM
        • LEAP PLATFORM
        • REDELEISH NETWORK
    • Close
  • ADVOCACY
      • ADVOCACY UPDATES
      • ACCESS
      • INTELLECTUAL PROPERTY
    • Close
  • MEDIA CENTRE
        • OVERVIEW
        • NEWS, VIEWS & STORIES
        • PRESS RELEASES
        • PRESS KIT
        • IN THE MEDIA
        • OUR PUBLICATIONS
        • E-NEWS NEWSLETTER
        • VIDEOS
        • SCIENTIFIC ARTICLES
        • EVENTS
    • Close
  • PARTNERS
      • OVERVIEW
      • BUSINESS MODEL
      • PARTNERS
      • BECOME A DNDi PARTNER
    • Close
  • DONATE
      • DONATE
      • HOW TO HELP
      • DONORS
      • KEY FINANCIAL FIGURES
    • Close
    • Close
  • Home
  • Media Centre
  • In the Media

In the Media

Chemical & Engineering News [29 January 2019]

“Open-source drug discovery takes aim at malaria and neglected diseases”

Click here to read the article

In the MediaDrug discovery, Partnership

Post navigation

Previous
Pharmaceutical Technology: “MMV and DNDi create a response box to foster R&D for pandemic diseases”
Next
Science & Enterprise: “Compounds made available for pandemic drug discovery”

Media Centre

  • Overview
  • News, Views & Stories
    • News
    • Viewpoints
    • Stories
  • Press Releases
    • Press Releases – Other Languages
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • Previous years
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010
      • 2009
      • 2008
      • 2007
      • 2006
      • 2005
      • 2004
      • 2003
  • Press Kit
  • In the Media
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • Previous years
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010
      • 2009
      • 2008
      • 2007
      • 2006
    • Radio
    • Television
  • Our Publications
  • E-news Newsletter
  • Videos
  • Scientific Articles
    • Human African Trypanosomiasis (Sleeping Sickness)
    • Visceral Leishmaniasis
    • Cutaneous Leishmaniasis
    • Filarial diseases
    • Chagas Disease
    • Mycetoma
    • Malaria
    • Neglected Diseases
    • Paediatric HIV
    • Hepatitis C
    • GARDP
  • Events
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • Previous years
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010
      • 2009
      • 2008
      • 2007
      • 2006
      • 2005
      • 2004
      • 2003

Recent Articles

  • DDNews: “Duo ‘AIMS’ at AI-powered discovery efforts”
  • Un Seul Monde – SDC Magazine: “Partnerships that save lives”
  • Health Policy Watch: “Negotiators agree on game-changing WHA resolution for medicine price disclosure”

Media Centre Search

Category
Diseases
Topic
Year

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

Learn More

  • Vision & Mission
  • Business Plan
  • DNDi‘s Model
  • Diseases & Projects
  • Portfolio
  • Treatments developed
  • Clinical Trials
  • Annual Report
  • Scientific Articles
  • Contact Us

Work with Us

  • Donate
  • Partnership
  • Requests for Proposals
  • Jobs

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

Newsletter

Sign up for the E-news newsletter! By subscribing, you agree that all info submitted will be processed according to our Privacy Policy. You can unsubscribe any time.

I want to receive

  • PRIVACY POLICY
  • TERMS OF USE
  • ACCEPTABLE USE POLICY
  • COOKIE POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Read Cookie Policy. Close